By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation and analyze site usage. This site uses cookies as described in our Privacy Policy and Terms of Use.
Pipeline

We have a broad and differentiated pipeline of investigational drugs across our family of companies.

Cellular Background

11

positive Phase 3 trials since 2019

We have run numerous large successful international Phase 3 clinical trials.

Agnostic to therapeutic area and modality

Our pipeline includes innovative product candidates across numerous therapeutic areas.

Small Molecule · Priovant
Brepocitinib
Dermatomyositis
Registrational
Small Molecule · Priovant
Brepocitinib
Non-Infectious Uveitis
Registrational
Small Molecule · Priovant
Brepocitinib
Cutaneous Sarcoidosis
Proof of Concept
Biologic · Immunovant
IMVT-1402
Graves' Disease
Registrational
Biologic · Immunovant
IMVT-1402
Difficult-to-Treat Rheumatoid Arthritis
Registrational
Biologic · Immunovant
IMVT-1402
Myasthenia Gravis
Registrational
Biologic · Immunovant
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Registrational
Biologic · Immunovant
IMVT-1402
Sjögren’s Disease
Registrational
Biologic · Immunovant
IMVT-1402
Cutaneous Lupus Erythematosus
Proof of Concept
Biologic · Immunovant
Batoclimab
Thyroid Eye Disease
Registrational
Inhaled · Pulmovant
Mosliciguat
Pulmonary Hypertension associated with Interstitial Lung Disease
Proof of Concept
video section decoration

Roivant CEO Matt Gline's presentation at the 2025 J.P. Morgan Healthcare Conference